What Is ADMET Data? Its Role in Drug Discovery and Development

What Is ADMET Data? Its Role in Drug Discovery and Development

A lot of drug candidates don’t fail because they “don’t work” (i.e. they’re not active). They fail because the body doesn’t cooperate, exposure is wrong, the molecule doesn’t behave as you’d expect, or the safety profile isn’t apparent until too late. On further investigation, it’s always the same problem: ADMET.

In plain English, ADMET data enables you to predict whether a compound is actually going to be a viable medicine (i.e., not just a very good molecule). In the current state of the art in the pipelines, ADMET data is not something you just tick a box for at the end of discovery. It is actually a layer of decision-making that will determine which projects you optimise, which ones you go on to test and which ones you kill off early. That is why ADMET in drug discovery has become a fundamental strategy rather than a peripheral activity.

This post by DrugsVault is a breakdown of what ADMET is, what constitutes ADMET data, how teams generate it, how it’s used throughout the process, and what “good ADMET” will look like in 2026.

What Does ADMET Stand For? (Absorption, Distribution, Metabolism, Excretion, Toxicity)

ADMET is an acronym for five “key” questions that every drug candidate has to answer.

Absorption: How Does the Compound Get into the Systemic Circulation?

Think about permeability, solubility and whether it can actually get into the body at a usable level.

Distribution: Where Does It Go Once It’s In?

Does it remain in the plasma, bind very heavily to proteins or accumulate in tissues such as the liver or the brain?

Metabolism: How Is It Altered?

The enzymes involved, the rate of the process and the potential hazards of the metabolites produced.

Excretion: How Is It Cleared?

Renal, biliary or other routes and how long it lasts (half life).

Toxicity: What Safety Hazards Are There?

Cytotoxicity, liver signals, cardiac risk, genotoxicity, off-target effects and the like.

The key point is that ADMET isn’t “preclinical only”. It’s looked at by the teams from the very start and is continually re-evaluated as the chemistry of the team progresses.

What Is ADMET Data? (Plain-English Definition)

ADMET data is structured information (measured or predicted) that describes how a drug behaves in the body and how safe it may be.

It usually comes in three forms:

Experimental Data

  • In vitro assays (cells, microsomes, transporter systems)
  • In vivo studies (animal PK, exposure, tox signals)
  • Clinical signals (when available)
  • Human PK/PD observations
  • Early safety signals
  • Drug-drug interaction (DDI) outcomes

In Silico Predictions

  • QSAR models
  • ML/AI predictions
  • Physics-based or hybrid approaches
Oral medication capsules and microscope on a lab bench illustrating absorption and metabolism studies for ADMET in drug discovery.

You’ll also hear people talking about curated collections being used to train the models, to benchmark the predictions and to screen the candidates. Those are typically packaged up as ADMET datasets.

Why ADMET Data Matters in Drug Discovery and Development

ADMET is essentially a de-risking layer. It reduces the chance that you’ve spent months optimising potency only to find the compound can’t get to the target tissue, can’t be dosed, or has an unacceptable interaction profile.

What ADME/Tox affects:

Selection of Lead Compounds

You pick the compound that you’re going to develop into a drug, it’s not just the one with the best IC50.

Dose Strategy and Formulation Considerations

Dissolution and elimination will have a major bearing on your decision as to whether you use a prodrug, a salt, a modified release drug or a new route.

Safety Profiling & Regulatory Preparedness

Tox findings point to what you should go on to test and what you should record.

Cost and Timeline Reduction

Fewer late-stage surprises means fewer expensive resets.

Most importantly, ADMET in drug discovery becomes a decision-making tool rather than a tick box. It helps the team to decide what to build, what to fix and what to stop.

ADMET in Drug Discovery: Where It Fits in the Pipeline

ADMET shows up differently depending on stage:

Discovery (Hit-to-Lead, Lead Optimization)

Fast screening + triage. You’re doing the filtering and triaging of chemistry.

Preclinical

Deeper profiling, species translation, toxicology studies and exposure planning.

Clinical

PK/PD monitoring, safety signals and DDI risk in the presence of real people.

Post-Market (As Appropriate)

Safety monitoring and signal detection.

Core ADMET Categories and Typical Measurements

Here are the main types of data to monitor, what is being measured and why it’s important.

Absorption Data

What it measures: solubility, permeability, dissolution and bioavailability.

Why it matters: if absorption is poor you may never achieve therapeutic exposure.

Common indicators include:

  • Solubility across pH ranges
  • Permeability proxies (high level)
  • Bioavailability estimates
  • “Food effect” concepts (high level)

Distribution Studies

Measurement: distribution and sites of accumulation of the compound.

Relevance: distribution affects both efficacy (will it get to the site of action?) and safety (does it accumulate in the wrong place?).

Typical measurements:

  • Plasma protein binding
  • Volume of distribution (Vd)
  • Tissue penetration (for example CNS penetration)
  • The role of transporters and effect on barriers

Data for Metabolism

What it assesses: transformation and its pathways

Why it’s important: leads to clearance, variability, toxic metabolites and DDIs.

Common measurements:

  • Metabolic stability
  • CYP inhibition and induction risk
  • Metabolite identification (high level)
  • Clearance pathway mapping

Excretion Data

What it measures: how the compound is cleared and how long it persists.

Significance: Excretion dictates the dosing frequency, the potential for accumulation and the degree of interpatient variability.

Commonly measured values:

  • Renal clearance
  • Biliary excretion indicators
  • Half-life
  • Total clearance

Toxicity Indicators

Measurement: The safety hazards and the potential for adverse effects.

Significance: Toxicity markers could lead to the entire development programme being scrapped or could require such a low dose that the drug would be rendered useless.

Common areas:

  • Cytotoxicity
  • Hepatotoxicity
  • Cardiotoxicity (including QT-related risk, high level)
  • Genotoxicity
  • Off-target signals and safety margins

Experimental vs Predicted ADMET Data (and How Teams Use Both)

Both are useful, just in different ways.

Experimental Strengths

  • Higher confidence
  • Stronger regulatory relevance
  • Better for confirming a go/no-go decision

Predicted Strengths

  • Fast and scalable
  • Useful for early filtering
  • Helps prioritize which experiments to run first

Best practice in 2026 looks like this:

  • Use predictions to triage and prioritize experiments
  • Confirm with lab data
  • Track where predictions consistently over- or under-estimate outcomes
  • Avoid treating model outputs as truth without domain checks

ADMET Datasets: What Makes Them “High Quality” (Checklist)

Not all datasets are equally useful. A good ADMET dataset is one that is consistent, well-documented and traceable.

Checklist for strong dataset quality:

  • Clear assay definitions and consistent protocols
  • Standard units and normalization rules
  • Complete metadata (species, cell line, conditions, timepoints)
  • Reproducibility indicators and error ranges
  • Coverage across relevant chemical space (not just “easy” compounds)
  • Versioning and provenance (where it came from, when it changed)

If you can’t explain the assay context and the origin of the data, then you can’t possibly use it for modelling or for any decision-making.

How ADMET Data Improves Decision-Making (Practical Use Cases)

This is where ADMET becomes real rather than just theoretical.

  • Early triage: eliminate compounds with poor developability before they soak up months
  • Lead optimization: guide chemistry changes toward better PK and safer profiles
  • DDI risk management: flag metabolism and transporter signals early
  • Candidate selection: balance potency with exposure, clearance, and safety margins
  • Portfolio strategy: compare programs using consistent benchmarks and thresholds

Common Challenges with ADMET Data (and How to Solve Them)

ADMET is powerful, just messy in practice. Common issues include:

  • Data fragmentation across teams and tools
  • Inconsistent assays and units across sources
  • Missing metadata and limited reproducibility
  • Model drift and “black box” predictions
  • Translational gaps (in vitro → in vivo → human)

Solving these typically requires more than “better models” it requires better data ops.

Best Practices for Managing ADMET Data in 2026

If you want ADMET to be driving the decisions, then treat it like a product not a spreadsheet.

Best practices:

  • Standardize schemas and naming conventions across teams
  • Use a centralized repository with versioning and access controls
  • Automate QC checks (unit validation, outlier detection)
  • Combine experimental + predicted data with traceability
  • Build dashboards that connect ADMET to go/no-go decisions
  • Maintain a small set of benchmark compounds for ongoing validation
Pharmaceutical scientist inspecting a formulation vial while recording pharmacokinetic parameters and ADMET data.

Conclusion

Potency gets the attention, but it’s ADMET that ultimately determines whether a compound can actually survive in the real world. If you treat ADMET as a continuous process, then you make faster decisions, you reduce the number of late-stage failures and you end up with actually developable candidates.

If there’s one thing to take away: good ADMET practice is not about gathering more data. It’s about gathering the right data, in a consistent format, with clear provenance and using that data to make decisions as early as possible.

FAQs

1. What Is the Difference Between ADMET Data and PK Data?

PK (pharmacokinetics) focuses mainly on exposure over time (concentration, AUC, Cmax, half-life). ADMET is broader: it includes PK-related elements plus metabolism pathways, distribution behavior, excretion routes, and toxicity risk.

2. When Should Teams Start Evaluating ADMET in Drug Discovery?

As early as hit-to-lead. Early ADMET screens help avoid optimizing potency on compounds that are unlikely to be developable, and they guide chemistry toward better real-world profiles.

3. What Makes ADMET Datasets Useful for AI and Predictive Modeling?

Consistency and context. Datasets are most useful when assays are clearly defined, units are standardized, metadata is complete, and versioning/provenance are tracked so models can be trained and validated reliably.

Make Smarter Drug Discovery Decisions with Reliable ADMET Data

Accelerate compound screening, improve lead optimization, and reduce late-stage development risks with structured, high-quality ADMET datasets that support more informed drug discovery decisions.